Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective

Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2272
https://www.valueinhealthjournal.com/article/S1098-3015(14)04202-8/fulltext
Title : Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04202-8&doi=10.1016/j.jval.2014.08.2272
First page : A634
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 1733
Categories :
Tags :
Regions :
ViH Article Tags :